CZ200487A3 - Léčivo pro zvýšení účinnosti terapie rakoviny - Google Patents
Léčivo pro zvýšení účinnosti terapie rakoviny Download PDFInfo
- Publication number
- CZ200487A3 CZ200487A3 CZ200487A CZ200487A CZ200487A3 CZ 200487 A3 CZ200487 A3 CZ 200487A3 CZ 200487 A CZ200487 A CZ 200487A CZ 200487 A CZ200487 A CZ 200487A CZ 200487 A3 CZ200487 A3 CZ 200487A3
- Authority
- CZ
- Czechia
- Prior art keywords
- use according
- galectin
- modified pectin
- administration
- compound
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 20
- 230000001965 increasing effect Effects 0.000 title abstract description 5
- 238000011275 oncology therapy Methods 0.000 title abstract description 5
- 102000007563 Galectins Human genes 0.000 claims abstract description 33
- 108010046569 Galectins Proteins 0.000 claims abstract description 33
- 238000002512 chemotherapy Methods 0.000 claims abstract description 10
- 238000001356 surgical procedure Methods 0.000 claims abstract description 8
- 239000001814 pectin Substances 0.000 claims description 32
- 229920001277 pectin Polymers 0.000 claims description 32
- 235000010987 pectin Nutrition 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 26
- 102000000802 Galectin 3 Human genes 0.000 claims description 25
- 108010001517 Galectin 3 Proteins 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 238000002560 therapeutic procedure Methods 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 13
- 238000001959 radiotherapy Methods 0.000 claims description 9
- 102000000795 Galectin 1 Human genes 0.000 claims description 7
- 108010001498 Galectin 1 Proteins 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 229920002230 Pectic acid Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 3
- 239000010318 polygalacturonic acid Substances 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 5
- 238000011200 topical administration Methods 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 abstract description 15
- 206010027476 Metastases Diseases 0.000 abstract description 12
- 230000033115 angiogenesis Effects 0.000 abstract description 10
- 230000009401 metastasis Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 8
- 230000000174 oncolytic effect Effects 0.000 abstract description 4
- 230000005855 radiation Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 34
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000011443 conventional therapy Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940045109 genistein Drugs 0.000 description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 4
- 235000006539 genistein Nutrition 0.000 description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 4
- 230000008611 intercellular interaction Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000031146 intracellular signal transduction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108010038196 saccharide-binding proteins Proteins 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 230000025164 anoikis Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001488 beta-D-galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000032341 cell morphogenesis Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000021309 simple sugar Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000004293 human mammary gland Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- -1 pectin Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29999101P | 2001-06-21 | 2001-06-21 | |
| US10/176,235 US6680306B2 (en) | 2001-06-21 | 2002-06-20 | Method for enhancing the effectiveness of cancer therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ200487A3 true CZ200487A3 (cs) | 2004-10-13 |
Family
ID=26872020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ200487A CZ200487A3 (cs) | 2001-06-21 | 2002-06-21 | Léčivo pro zvýšení účinnosti terapie rakoviny |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6680306B2 (enExample) |
| EP (1) | EP1406639A4 (enExample) |
| JP (1) | JP2004535430A (enExample) |
| CN (1) | CN100558367C (enExample) |
| AU (1) | AU2002320140B2 (enExample) |
| BR (1) | BR0210550A (enExample) |
| CA (1) | CA2451841A1 (enExample) |
| CZ (1) | CZ200487A3 (enExample) |
| IL (1) | IL159461A0 (enExample) |
| MX (1) | MXPA03012021A (enExample) |
| WO (1) | WO2003000118A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440555A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20030004132A1 (en) * | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
| US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US20040121981A1 (en) * | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US20040259816A1 (en) * | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
| AU2004229399B2 (en) * | 2003-04-07 | 2010-08-05 | Prospect Therapeutics, Inc. | Composition and uses of galectin antagonists |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2005007110A2 (en) * | 2003-07-11 | 2005-01-27 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
| DE10335236B3 (de) * | 2003-08-01 | 2005-02-24 | Drägerwerk AG | Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom |
| US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US20050282773A1 (en) * | 2004-01-14 | 2005-12-22 | Pro-Pharmaceuticals, Inc. | Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer |
| EP1718146A2 (en) * | 2004-02-13 | 2006-11-08 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
| CA2582428A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| WO2006020027A1 (en) * | 2004-07-14 | 2006-02-23 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
| EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
| BRPI0607579A2 (pt) * | 2005-03-23 | 2009-09-15 | Pfizer Prod Inc | uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer |
| US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
| US7919250B2 (en) * | 2007-07-31 | 2011-04-05 | New York University | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
| CA2778953C (en) | 2009-11-13 | 2020-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
| EP2788761B1 (en) * | 2011-12-08 | 2018-02-28 | Eliaz Therapeutics, Inc. | Reduction of galectin-3 levels by plasmapheresis |
| KR101968370B1 (ko) * | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
| WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| ES2848538T3 (es) | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| BR112015005772A2 (pt) | 2012-09-17 | 2017-08-08 | Galectin Therapeutics Inc | método para a intensificação de imunoterapias específicas no tratamento de câncer |
| JP6055928B2 (ja) | 2012-10-10 | 2016-12-27 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA2930817A1 (en) | 2013-11-17 | 2015-05-21 | Rdd Pharma Ltd. | Methods for treating radiation induced gastrointestinal tract injury |
| CA3031691A1 (en) * | 2016-09-13 | 2018-03-22 | Rasna Research Inc. | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US107222A (en) * | 1870-09-13 | Improvement in machines for tenoning window-sash | ||
| US5490991A (en) | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| US5843442A (en) | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
| US5639737A (en) | 1991-11-04 | 1997-06-17 | Co Enzyme Technology Ltd. | Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors |
| US20020107222A1 (en) | 1993-03-01 | 2002-08-08 | David Platt | Modified polysaccharides for treatment of cancer |
| US5490911A (en) * | 1993-11-26 | 1996-02-13 | The United States Of America As Represented By The Department Of Energy | Reactive multilayer synthesis of hard ceramic foils and films |
| US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5681923A (en) | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
| KR19990087665A (ko) * | 1996-03-15 | 1999-12-27 | 오미야 히사시 | 우론산의 가열-처리 산물, 이를 함유하는 식품, 음료 또는 약제 |
| US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
| EP1391206B1 (en) * | 1997-10-15 | 2008-07-02 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
| US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
| US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| US6274566B1 (en) * | 1999-02-23 | 2001-08-14 | Econugenics, Inc. | Methods for treating mammals with modified alginates and pectins |
| WO2002026262A2 (en) | 2000-09-25 | 2002-04-04 | Pro-Pharmaceuticals, Inc. | Compositions for reducing side effects in chemotherapeutic treatments |
| US20020104222A1 (en) * | 2001-02-06 | 2002-08-08 | Jay Larry Dean | Knife for removing the hide of an animal and method therefor |
| US6914055B2 (en) * | 2001-03-27 | 2005-07-05 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6645946B1 (en) * | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6982255B2 (en) * | 2001-03-27 | 2006-01-03 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| WO2002076474A1 (en) | 2001-03-27 | 2002-10-03 | Pro-Pharmaceuticals, Inc. | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2006020027A1 (en) * | 2004-07-14 | 2006-02-23 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
-
2002
- 2002-06-20 US US10/176,235 patent/US6680306B2/en not_active Expired - Fee Related
- 2002-06-21 BR BR0210550-0A patent/BR0210550A/pt not_active IP Right Cessation
- 2002-06-21 CN CNB028160037A patent/CN100558367C/zh not_active Expired - Fee Related
- 2002-06-21 JP JP2003506572A patent/JP2004535430A/ja active Pending
- 2002-06-21 WO PCT/US2002/019885 patent/WO2003000118A2/en not_active Ceased
- 2002-06-21 EP EP02749641A patent/EP1406639A4/en not_active Withdrawn
- 2002-06-21 MX MXPA03012021A patent/MXPA03012021A/es not_active Application Discontinuation
- 2002-06-21 IL IL15946102A patent/IL159461A0/xx unknown
- 2002-06-21 AU AU2002320140A patent/AU2002320140B2/en not_active Ceased
- 2002-06-21 CZ CZ200487A patent/CZ200487A3/cs unknown
- 2002-06-21 CA CA002451841A patent/CA2451841A1/en not_active Abandoned
-
2003
- 2003-04-07 US US10/408,723 patent/US20040023925A1/en not_active Abandoned
- 2003-09-08 US US10/657,383 patent/US20040043962A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03012021A (es) | 2004-06-03 |
| EP1406639A4 (en) | 2004-07-28 |
| US6680306B2 (en) | 2004-01-20 |
| AU2002320140B2 (en) | 2007-11-29 |
| EP1406639A2 (en) | 2004-04-14 |
| BR0210550A (pt) | 2004-05-25 |
| US20040043962A1 (en) | 2004-03-04 |
| WO2003000118A2 (en) | 2003-01-03 |
| US20040023925A1 (en) | 2004-02-05 |
| CA2451841A1 (en) | 2003-01-03 |
| IL159461A0 (en) | 2004-06-01 |
| CN1543351A (zh) | 2004-11-03 |
| JP2004535430A (ja) | 2004-11-25 |
| WO2003000118A3 (en) | 2003-04-10 |
| CN100558367C (zh) | 2009-11-11 |
| US20030013681A1 (en) | 2003-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ200487A3 (cs) | Léčivo pro zvýšení účinnosti terapie rakoviny | |
| AU2002320140A1 (en) | Method for enhancing the effectiveness of cancer therapies | |
| Koyanagi et al. | Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities | |
| US20070141101A1 (en) | Method for stimulating angiogenesis and wound healing | |
| SK459890A3 (en) | USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT | |
| RU2009132663A (ru) | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| JP5484320B2 (ja) | ナリンゲニンとナリンジンを形質転換成長因子−β１のシグナル経路阻害剤とする使用 | |
| JPH0225415A (ja) | 癌転移抑制剤 | |
| Vitale et al. | Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression | |
| Alam et al. | Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate) | |
| Raju et al. | Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases | |
| CN108186643B (zh) | 一种具有协同抗骨肉瘤功效的药物组合物及其应用 | |
| KR100822357B1 (ko) | 성장 인자 ｆｇｆ-2의 변경된 활성화에 의해 야기된질병의 치료를 위한 긴 펜트락신 ｐｔｘ3의 용도 | |
| JPS6366128A (ja) | 動物およびヒト癌の治療に用いられるｃ反応性タンパク質 | |
| KR19990072058A (ko) | 히알루론산 수용체 결합물질과 이의 용도 | |
| Jakobsson et al. | Protamine and mast-cell-mediated angiogenesis in the rat | |
| DE60030567D1 (de) | Aus muskeln abstammenden wirkstoffe enthaltende zusammensetzung | |
| AU2020255063B2 (en) | Combined use of A-nor-5α androstane compound drug and anticancer drug | |
| AU2014225496B2 (en) | Kits and methods for the treatment of cancer using gliadin peptides | |
| TW200306200A (en) | Use of long pentraxin PTX3 for the preparation of a medicine for the treatment of tumour diseases associated with abnormal activation of growth factor FGF-8 | |
| Nagasaki et al. | Heparin potentiates the action of plasma membrane‐associated growth stimulatory activity | |
| CN116327772B (zh) | SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法 | |
| Tortora et al. | Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents | |
| CN110876803B (zh) | 一种包含乳蛋白和油酸的药物组合物 | |
| Khochenkov et al. | Antiangiogenic activity of alofanib, an allosteric inhibitor of fibroblast growth factor receptor 2 |